Sirpiglenastat

Cat. No.: HY-132832
CAS No.: 2079939-05-0
Molecular Formula: C\textsubscript{22}H\textsubscript{27}N\textsubscript{5}O\textsubscript{5}
Molecular Weight: 441.48
Target: Others
Pathway: Others
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

**BIOLOGICAL ACTIVITY**

**Description**
Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response\(^1\)[\(^2\)].

**In Vitro**
Sirpiglenastat (DRP-104) treatment shows broad immune cell modulation effects including increased T, NK, and macrophages. Sirpiglenastat decreases pro-tumorigenic cytokines such as VEGF and KC (IL-8)\(^1\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**
CT26 bearing mice treated with Sirpiglenastat (DRP-104) (0.5 mg/kg; s.c.; once a day; for 5 days) shows tumor growth inhibition at day 12 of 90%. Median survival days are 36 days\(^1\).
Sirpiglenastat (0.5 mg/kg; s.c.) treatment significantly inhibits tumor growth in the H22 model\(^1\).

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

<table>
<thead>
<tr>
<th>Animal Model:</th>
<th>CT26 bearing mice(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage:</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>Administration:</td>
<td>s.c.; once a day; for 5 days</td>
</tr>
<tr>
<td>Result:</td>
<td>Showed tumor growth inhibition in mice.</td>
</tr>
</tbody>
</table>

**REFERENCES**

